0001209191-20-036807.txt : 20200615
0001209191-20-036807.hdr.sgml : 20200615
20200615193927
ACCESSION NUMBER: 0001209191-20-036807
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20200611
FILED AS OF DATE: 20200615
DATE AS OF CHANGE: 20200615
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Cheruvu Pavan
CENTRAL INDEX KEY: 0001731741
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-37418
FILM NUMBER: 20964617
MAIL ADDRESS:
STREET 1: C/O AXOVANT SCIENCES, INC.
STREET 2: 11 TIMES SQUARE, 33RD FLOOR
CITY: NEW YORK
STATE: NY
ZIP: 10036
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Axovant Gene Therapies Ltd.
CENTRAL INDEX KEY: 0001636050
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 981333697
FISCAL YEAR END: 0331
BUSINESS ADDRESS:
STREET 1: 11-12 ST. JAMES'S SQUARE
STREET 2: SUITE 1, 3RD FLOOR
CITY: LONDON
STATE: X0
ZIP: SW1Y 4LB
BUSINESS PHONE: 44 203 318 9708
MAIL ADDRESS:
STREET 1: 11 TIMES SQUARE
STREET 2: 33RD FLOOR
CITY: NEW YORK
STATE: NY
ZIP: 10036
FORMER COMPANY:
FORMER CONFORMED NAME: Axovant Sciences Ltd.
DATE OF NAME CHANGE: 20150324
FORMER COMPANY:
FORMER CONFORMED NAME: Axovant Sciences, Inc.
DATE OF NAME CHANGE: 20150324
FORMER COMPANY:
FORMER CONFORMED NAME: Roivant Neurosciences Ltd.
DATE OF NAME CHANGE: 20150309
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2020-06-11
0
0001636050
Axovant Gene Therapies Ltd.
AXGT
0001731741
Cheruvu Pavan
C/O AXOVANT GENE THERAPIES LTD.
11 TIMES SQUARE, 33RD FLOOR
NEW YORK
NY
10036
1
1
0
0
Principal Executive Officer
Common Shares
2020-06-11
4
A
0
22591
0.00
A
30091
D
Common Shares
2020-06-11
4
F
0
9755
3.09
D
20336
D
Restricted Stock Units
2020-06-11
4
D
0
22591
0.00
D
Common Shares
22591
22590
D
The shares were sold on behalf of the Reporting Person in the open market to cover withholding taxes relating to the settlement of the vested restricted stock units.
Each restricted stock unit represents the right to receive one share of the Issuer's common stock. 50% of the common shares underlying the restricted stock units vested on January 31, 2020 but settlement of such portion of the restricted stock units was delayed until transactions acceptable under the Issuer's insider trading policy were permitted.
50% of the common shares underlying the restricted stock units vest on January 31, 2020 and the remainder vest on July 31, 2020, subject to the Reporting Person providing continuous service to the Issuer through each such date.
/s/ Alison Haggerty, Attorney-In-Fact
2020-06-15